







Compendium
of data and
evidence-related
tools for use in
TB planning and
programming



Compendium of data and evidence-related tools for use in TB planning and programming

ISBN 978-92-4-002284-3 (electronic version)

ISBN 978-92-4-002285-0 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Compendium of data and evidence-related tools for use in TB planning and programming. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements	iv
Abbreviations	\
Chapter 1. Introduction	1
Chapter 2. Overview of data and evidence-related tools	3
2.1 Types of tools	4
2.2 Contents of tool profiles	5
2.3 How to use the compendium	7
2.4 Considerations for tool implementation	11
Chapter 3. Tool profiles	13
3.1 Drug-resistance surveys	14
3.2 Inventory studies	20
3.3 Operational/implementation research	28
3.4 Patient cost surveys	32
3.5 National TB prevalence surveys	36
3.6 TB service delivery costing studies	42
3.7 Care cascade analysis	48
3.8 OneHealth tool for TB budgeting	54
3.9 Diagnostic network optimization	60
3.10 Epidemiological modelling	66
3.11 MATCH	70
3.12 Patient pathway analysis	74
3.13 Private sector drug sales	78
3.14 ScreenTB	82
3.15 Standards and benchmarks assessment	86
3.16 Mini-profiles	91
Chapter 4. Country implementation	93
References	97
Annex	
Overview of the people-centred framework for TB programme planning and prioritization	105

Acknowledgements

The Compendium of data and evidence-related tools for use in TB planning and programming was developed as a companion document to the People-centred framework for tuberculosis programme planning and prioritization – user guide, published by the World Health Organization (WHO) in 2019. The compendium is intended to support implementation of the people-centred framework user guide. It can also be used independently to inform decisions taken by national tuberculosis (TB) programmes about the implementation of the tools included in this document.

This compendium was developed through a collaborative partnership between WHO and various partners. The following institutions contributed to the tools included in Chapter 3 of this compendium: the Bill & Melinda Gates Foundation, the Foundation for Innovative New Diagnostics, the TB Modelling Analysis Consortium, the Special Programme for Research and Training in Tropical Diseases, the Royal Tropical Institute Netherlands, the KNCV Tuberculosis Foundation, Linksbridge and the United States Agency for International Development. The development of the document also benefited from inputs from the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Stop TB Partnership and the United States Centers for Disease Control and Prevention.

WHO would also like to thank the national TB programmes of Bangladesh, Cambodia, the Democratic Republic of the Congo, Eswatini, Ethiopia, India, Indonesia, Kenya, the Philippines, South Africa and Viet Nam for their willingness to share their experiences in implementing the tools through the case studies included in the document.

The preparation and publication of the compendium was funded from a grant provided to WHO by the Bill & Melinda Gates Foundation.

Abbreviations

ACF active case finding

AIDS acquired immunodeficiency syndrome

CI confidence interval

DHS demographic and health survey

DNA deoxyribonucleic acid DOT directly observed treatment

DR-TB drug-resistant TB DS-TB drug-susceptible TB DST drug-susceptibility testing

FIND Foundation for Innovative New Diagnostics

GHCC Global Health Cost Consortium

Global Fund Global Fund to Fight AIDS, Tuberculosis and Malaria

GΡ general practitioner

HEUS health expenditure and utilization survey

human immunodeficiency virus HIV KNCV **KNCV Tuberculosis Foundation**

LSHTM London School of Hygiene & Tropical Medicine

M&E monitoring and evaluation

MATCH mapping and analysis for tailored disease control and health system strengthening

MDR-TB multidrug-resistant TB MFL master facility list MoH ministry of health N/A not applicable

NGO nongovernmental organization

NHIF National Health Insurance Fund (Kenya)

NTLCP National Tuberculosis and Leprosy Control Programme (Ethiopia) NTLD National Tuberculosis, Leprosy and Lung Disease Programme (Kenya)

NTP national TB programme NSP national strategic plan OHT

OneHealth tool

OR/IR operational research and implementation research

PhilHealth Philippine Health Insurance Corporation

PPA patient pathway analysis PPM public-private mix RR-TB rifampicin-resistant TB

SITT Sistem Informasi Tuberkulosis Terpadu (Indonesia)

SRL supranational reference laboratory

TB tuberculosis

TB MAC TB Modelling and Analysis Consortium TIME tuberculosis impact module and estimates

UCT University of Cape Town

UN **United Nations**

US CDC United States Centers for Disease Control and Prevention **USAID** United States Agency for International Development

WHO World Health Organization



https://www.yunbaogao.cn/report/index/report?reportId=5_23522

